Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases - Tabular View

Tracking Information

First Received Date ^ICMJE

August 4, 2005

Last Updated Date

October 9, 2008

Start Date ^ICMJE

November 2005

Primary Completion Date

Current Primary Outcome Measures ^ICMJE

Antibody levels after vaccination

Original Primary Outcome Measures ^ICMJE

Same as current

Change History

Complete list of historical versions of study NCT00127010 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^ICMJE

Safety of the study vaccines

Original Secondary Outcome Measures ^ICMJE

Safety of the study vacccines

Descriptive Information

Brief Title ^ICMJE

Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases

Official Title ^ICMJE

Blinded, Randomized Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Measles-Mumps-Rubella-Varicella Candidate Vaccine Given to Healthy Children During the Second Year of Life

Brief Summary

This is a study to evaluate the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals combined measles-mumps-rubella varicella candidate vaccine given to healthy children in their second year of life.

Detailed Description

This study included an active control group who received the licensed Priorix (measles, mumps, rubella [MMR] vaccine).

Study Phase

Phase III

Study Type ^ICMJE

Interventional

Study Design ^ICMJE

Prevention, Randomized, Open Label, Parallel Assignment, Safety Study

Condition ^ICMJE

Measles
Mumps
Rubella
Chickenpox

Intervention ^ICMJE

Biological: Measles, Mumps, Rubella and Chickenpox (live vaccine)

Study Arms / Comparison Groups

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Completed

Enrollment ^ICMJE

Completion Date

Primary Completion Date

Eligibility Criteria ^ICMJE

Inclusion Criteria:

A male or female subject between 11-13 months of age (i.e. from 11 month birthday until the day before the 14 month birthday) at the time of the first vaccination.

Exclusion Criteria:

History of previous measles, mumps, rubella and/or varicella vaccination or disease, or known exposure to any of these diseases within 30 days prior to the start of the trial
Planned administration of a vaccine not foreseen by the study protocol from 30 days prior to each vaccination until 42-56 days after each vaccination

Gender

Both

Ages

11 Months to 13 Months

Accepts Healthy Volunteers

Yes

Contacts ^ICMJE

Contact information is only displayed when the study is recruiting subjects

Location Countries ^ICMJE

Belgium, Germany

Administrative Information

NCT ID ^ICMJE

NCT00127010

Responsible Party

Study Director, GSK

Study ID Numbers ^ICMJE

103388

Study Sponsor ^ICMJE

GlaxoSmithKline

Collaborators ^ICMJE

Investigators ^ICMJE

Study Director:

GSK Clinical Trials

GlaxoSmithKline

Information Provided By

GlaxoSmithKline

Verification Date

October 2008

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP